Insulin requirements and residual beta-cell function 12 months after concluding immunotherapy in type I diabetic patients treated with combined azathioprine and thymostimulin administration for one year

scientific article published on 01 October 1990

Insulin requirements and residual beta-cell function 12 months after concluding immunotherapy in type I diabetic patients treated with combined azathioprine and thymostimulin administration for one year is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0896-8411(05)80030-7
P698PubMed publication ID2252531

P2093author name stringMonreal M
Subirá ML
Goñi F
Yoldi A
Oleaga A
Goñi MJ
Sevilla M
Moncada E
Sánchez-Ibarrola A
Terán D
P2860cites workIslet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficienciesQ28237011
Direct evidence for loss of human suppressor cells during active autoimmune diseaseQ35996534
Circulating thymic-hormone activity in congenital immunodeficiencyQ39450626
Multiple immunological abnormalities in patients with type 1 (insulin-dependent) diabetes mellitusQ39768907
Protein glycosylation in diabetes mellitus: a review of laboratory measurements and of their clinical utilityQ40144848
Factors associated with early remission of type I diabetes in children treated with cyclosporineQ41282880
Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in childrenQ42517345
Human interleukin 2.Q43867352
Interleukin 1 dose-dependently affects the biosynthesis of (pro)insulin in isolated rat islets of LangerhansQ43996137
Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosisQ44606337
Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent OnsetQ49173574
Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.Q53885179
IMMUNOLOGICAL FUNCTION OF THE THYMUSQ56623510
Delineation of the Thymic and Bursal Lymphoid Systems in the ChickenQ59068925
Radioimmunoassay of human proinsulin C-peptide using synthetic human connecting peptideQ68778239
Immunosuppressive therapy in diabetesQ69857709
Soluble immune response suppressor (SIRS)Q69877871
Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitusQ70201930
Histiocytosis-XQ70536356
P433issue5
P921main subjectazathioprineQ18939
immunotherapyQ1427096
P304page(s)625-638
P577publication date1990-10-01
P1433published inJournal of AutoimmunityQ15716783
P1476titleInsulin requirements and residual beta-cell function 12 months after concluding immunotherapy in type I diabetic patients treated with combined azathioprine and thymostimulin administration for one year
P478volume3

Reverse relations

cites work (P2860)
Q41605577Autoimmune diabetes. The role of autoantibody markers in the prediction and prevention of insulin-dependent diabetes mellitus.
Q40490594Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders
Q38927961Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes

Search more.